Sign Up to like & get
recommendations!
0
Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4063
Abstract: A significant fraction of advanced prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade (ICB) using antibodies against cytotoxic-T-lymphocyte-associated…
read more here.
Keywords:
mcrpc;
immunotherapy;
target immunosuppressive;
cancer ... See more keywords